An European Medicines Agency committee has recommended to the European Commission that the Janus kinase inhibitor 1 Abrocitinib be allowed to be sold in dosages of 100 mg. and 200 mg. and that a new indication be added for another Pfizer drug, XELJANZ(tofacitinib). Abrocitinib is for the treatment of moderate to severe atopic dermatitis in adults. The XELJANZ committee recommends approval for the treatment of adults with active ankylosing spondylitis.